

Colorectal Cancer Screening

The Power of FIT for Early Detection

Colorectal cancer (CRC) screening saves lives – especially when it is easy for patients and scalable for laboratories.

siemens-healthineers.com/en-au/colorectalcancer



Benefits of FIT testing using FOB Gold patient collection tube on the Atellica Portfolio

Sample collection

The patented 2-in-1 sample collection-dilution tube offers an easy to use, hygienic, and non-invasive solution for at-home sample collection.† With just a single sample required and no patient pre-preparation provides a seamless and private experience for the patients. Data indicate ease of patient collection is similar or superior to other commonly used FIT methods.*

Sample transport

By dissolving and diluting the patient sample in the buffer solution upon re-insertion of the collection stick, the process ensures the sample is properly prepared for easy and efficient transport to the testing site.

Automated testing

The patient collection tube is loaded directly onto the Atellica Solution with Atellica Integrated Automation, which automates decapping and testing workflow reducing operator hands-on time.

The patented design of the patient collection tube ensures consistent sample volume,† optimising accuracy and reliability for analytical testing.

The patient collection tube extracts and preserves haemoglobin from the stool sample, ensuring its stability across a broad temperature range, allowing for accurate testing upon transport to the laboratory.‡

The Atellica CH Sentinel FIT test integrates seamlessly into routine chemistry workflows, enabling labs to perform FIT testing with their routine chemistry tests. The Atellica Solution delivers results in 10 minutes and supports high throughput, improving efficiency and minimising turnaround time.



Ease of Use
Enhances patient compliance, preserves samples, and reduces laboratory hands-on time



Trust in Results
Proven assay design, fully supported by Siemens Healthineers



Operational Efficiency
Streamlining screening, reducing unnecessary procedures, and focusing resources on high-risk patients

*Data on file with Sentinel Diagnostics

†Sentinel Diagnostics FOB Gold Tube Screen IFU 11561H-5.0/02, 2023/11/09

‡Sentinel Diagnostics FOB Gold NG Wide IFU REF 1156009-5.0/02, 2023/09/21 and reference 43